EyePoint Pharmaceuticals (EYPT)
(Real Time Quote from BATS)
$11.52 USD
-0.07 (-0.60%)
Updated May 22, 2024 02:22 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for EYEPOINT PHARMACEUTICALS, INC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 46 | 41 | 37 | 34 | 20 |
Cost Of Goods | 5 | 8 | 8 | 6 | 3 |
Gross Profit | 41 | 33 | 29 | 29 | 18 |
Selling & Adminstrative & Depr. & Amort Expenses | 116 | 133 | 84 | 66 | 66 |
Income After Depreciation & Amortization | -75 | -100 | -55 | -37 | -48 |
Non-Operating Income | 6 | 1 | 2 | -1 | -3 |
Interest Expense | 1 | 3 | 6 | 7 | 6 |
Pretax Income | -71 | -102 | -58 | -45 | -57 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -71 | -102 | -58 | -45 | -57 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -71 | -102 | -58 | -45 | -57 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -75 | -77 | -52 | -34 | -45 |
Depreciation & Amortization (Cash Flow) | 0 | 23 | 3 | 3 | 3 |
Income After Depreciation & Amortization | -75 | -100 | -55 | -37 | -48 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 38.90 | 37.32 | 28.76 | 12.84 | 10.43 |
Diluted EPS Before Non-Recurring Items | -1.82 | -2.15 | -2.03 | -3.47 | -4.80 |
Diluted Net EPS (GAAP) | -1.82 | -2.74 | -2.03 | -3.54 | -5.40 |
Fiscal Year end for EYEPOINT PHARMACEUTICALS, INC falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 11.68 | 14.03 | 15.20 | 9.11 | 7.68 |
Cost Of Goods | 0.76 | 1.00 | 1.20 | 1.79 | 0.64 |
Gross Profit | 10.93 | 13.03 | 14.00 | 7.31 | 7.04 |
SG&A, R&D, and Dept/Amort Expenses | 44.25 | 29.38 | 28.40 | 30.07 | 28.60 |
Income After SG&A, R&D, and Dept/Amort Expenses | -33.32 | -16.35 | -14.40 | -22.76 | -21.56 |
Non-Operating Income | 4.04 | 2.34 | 1.79 | 0.28 | 1.20 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.44 | 0.81 |
Pretax Income | -29.28 | -14.02 | -12.61 | -22.92 | -21.16 |
Income Taxes | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -29.28 | -14.10 | -12.61 | -22.92 | -21.16 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -29.28 | -14.10 | -12.61 | -22.92 | -21.16 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 52.91 | 42.17 | 38.34 | 37.58 | 37.49 |
Diluted EPS Before Non-Recurring Items | -0.55 | -0.33 | -0.33 | -0.61 | -0.56 |
Diluted Net EPS (GAAP) | -0.55 | -0.32 | -0.33 | -0.61 | -0.56 |